Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Chest. 2010 Nov;138(5):1156-65. doi: 10.1378/chest.09-2426. Epub 2010 May 14.
Asthma is a major public health problem that affects millions of children worldwide, and exacerbations account for most of its morbidity and costs. Primary-care providers lack efficient tools to identify children at high risk for exacerbations. We aimed to construct a clinical score to help providers to identify such children.
Our main outcome was severe asthma exacerbation, which was defined as any hospitalization, urgent visit, or systemic steroid course for asthma in the previous year, in children. A clinical score, consisting of a checklist questionnaire made up of 17 yes-no questions regarding asthma symptoms, use of medications and health-care services, and history, was built and validated in a cross-sectional study of Costa Rican children with asthma. It was then evaluated using data from the Childhood Asthma Management Program (CAMP), a longitudinal trial cohort of North American children.
Compared with children at average risk for an exacerbation in the Costa Rican validation set, the odds of an exacerbation among children in the low-risk (OR, 0.2; 95% CI, 0.1-0.4) and high-risk (OR, 5.4; 95% CI, 1.5-19.2) score categories were significantly reduced and increased, respectively. In CAMP, the hazard ratios for an exacerbation after 1-year follow-up in the low-risk and high-risk groups were 0.6 (95% CI, 0.5-0.7) and 1.9 (95% CI, 1.4-2.4), respectively, with similar results at 2 years.
The proposed Asthma Exacerbation Clinical Score is simple to use and effective at identifying children at high and low risk for asthma exacerbations. The tool can easily be used in primary-care settings.
哮喘是一个全球性的重大公共卫生问题,影响着全球数以百万计的儿童,其发病率和费用主要与加重期相关。初级保健提供者缺乏有效的工具来识别易发生加重的儿童。我们旨在构建一种临床评分,以帮助提供者识别此类儿童。
我们的主要结局是严重哮喘加重,定义为过去 1 年中因哮喘住院、急诊就诊或全身使用皮质类固醇的任何情况。我们构建并验证了一种临床评分,该评分由一个包含 17 个是否问题的检查表组成,这些问题涉及哮喘症状、药物和医疗保健服务的使用以及病史。然后,我们使用来自北美儿童的哮喘管理计划(CAMP)的纵向试验队列的数据对其进行了评估。
与哥斯达黎加验证集中处于加重平均风险的儿童相比,低风险(比值比,0.2;95%置信区间,0.1-0.4)和高风险(比值比,5.4;95%置信区间,1.5-19.2)评分类别的儿童发生加重的可能性分别显著降低和升高。在 CAMP 中,低风险和高风险组在 1 年随访后发生加重的风险比分别为 0.6(95%置信区间,0.5-0.7)和 1.9(95%置信区间,1.4-2.4),2 年时也有类似结果。
提出的哮喘加重临床评分使用简便,可有效识别哮喘加重风险高和低的儿童。该工具易于在初级保健环境中使用。